{
  "docId": "019de074-ddab-749d-b286-5e01e8bcb935",
  "docSlug": "f43e68719e672319f390e5844d5bc5fe",
  "documentTitle": "Chimerix | Investor Presentation Deck | 41 slides",
  "authorId": "chimerix",
  "authorName": "Chimerix",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 3,
  "pageCount": 41,
  "prevPage": 2,
  "nextPage": 4,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 2,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-ddab-749d-b286-5e01e8bcb935/3",
  "deckHref": "/decks/019de074-ddab-749d-b286-5e01e8bcb935",
  "deckJsonHref": "/decks/019de074-ddab-749d-b286-5e01e8bcb935.json",
  "deckAnchorHref": "/decks/019de074-ddab-749d-b286-5e01e8bcb935#slide-3",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.72,
        "x": 0.14,
        "y": 0.13
      },
      "kind": "image",
      "text": null,
      "attrs": null,
      "subkind": "icon-grid",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b7a8c07c-d0f3-4f6b-9e78-84648ba7e82d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.3,
        "x": 0.04,
        "y": 0.47
      },
      "kind": "list",
      "text": "Phase 2 study designed to isolate single agent activity in difficult treatment setting; Durable responses associated with OS and other forms of clinical benefit; Numerous independent and natural disease history studies support potential survival advantage; Genetically selected patient population limits patient heterogeneity",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6383f0f4-4f00-462a-be4f-b4de514f3093",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.3,
        "x": 0.35,
        "y": 0.47
      },
      "kind": "list",
      "text": "Terminal disease with no effective therapeutic options; High awareness for program within neuro-oncology community; U.S. patent exclusivity through at least 2037; Global revenue potential of ~$750m in first indication alone",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ec751f73-ff56-4d1e-b610-486f374d881b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.3,
        "x": 0.66,
        "y": 0.47
      },
      "kind": "list",
      "text": "Leadership team successfully executed large scale studies and regulatory approvals; Strong balance sheet fully funds ACTION study and potential ONC206 catalysts; Opportunity for continued non-dilutive TEMBEXA milestones and royalties adds flexibility; Track record of objectivity in creating paths to capture value",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f061b916-63b2-4b93-a40b-bcaa4f9b6884",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.28,
        "x": 0.36,
        "y": 0.25
      },
      "kind": "paragraph",
      "text": "Low barriers to commercial potential for ONC201",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5d300f19-e970-4581-9285-6c8c636bc439",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.28,
        "x": 0.67,
        "y": 0.25
      },
      "kind": "paragraph",
      "text": "Corporate capability and financial flexibility",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "63745874-fd57-46af-a7ae-521a3693f97d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.28,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "paragraph",
      "text": "High probability of success for Phase 3 ACTION study of ONC201",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d8ef12e1-3596-4972-811a-18106af19309",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.32,
        "x": 0.34,
        "y": 0.04
      },
      "kind": "title",
      "text": "Investment highlights",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2cfbad3a-eb24-457e-8e4a-74cc307eb3b8",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "bdd0ba9d-d966-4905-a775-8ba1cb54724e",
      "evidence": "list/bullet: Phase 2 study designed to isolate single agent activity in difficult treatment setting; Durable responses associated with OS and other forms of clinical benefit; Numerous independent and natural disease hist",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}